158 filings
Page 6 of 8
8-K
b6di9rp67rf3l1l7lwy
12 Mar 20
Kezar Life Sciences Reports Fourth Quarter and Year End 2019 Financial Results and Provides Business Update
4:05pm
8-K
pysd8dims8 o8f
3 Feb 20
Kezar Announces Pricing of $49.4 Million Public Offering of Common Stock andPre-Funded Warrants
5:30pm
424B5
fdmvme
3 Feb 20
Prospectus supplement for primary offering
5:29pm
8-K
3pvvq05obfg3
30 Jan 20
Special Note Regarding Forward-looking Statements
4:15pm
424B5
2kt5jewjwf
30 Jan 20
Prospectus supplement for primary offering
4:10pm
8-K
7d9mnxm0rona xq
13 Jan 20
Results of Operations and Financial Condition
8:24am
8-K
stvlz5vc1bt
19 Dec 19
Departure of Directors or Certain Officers
3:49pm
8-K
tc08alp
12 Nov 19
Kezar Announces Promising New Data with KZR-616 at the American College of Rheumatology Annual Meeting
8:52am
8-K
pfi3h jvq8lm
6 Nov 19
Kezar Life Sciences Reports Third Quarter 2019 Financial Results and Provides Business Update
4:15pm
8-K
4lgizrh3zkk1eb97yy4
3 Oct 19
Regulation FD Disclosure
4:05pm
8-K
16bgbo xrbmh
7 Aug 19
Kezar Life Sciences Reports Second Quarter 2019 Financial Results and Provides Business Update
4:05pm
EFFECT
t7n06wbr
12 Jul 19
Notice of effectiveness
12:15am
UPLOAD
513cctmt
9 Jul 19
Letter from SEC
12:00am
CORRESP
m8vmdl
9 Jul 19
Correspondence with SEC
12:00am
S-3
g4z89md2 khyr9s3e
3 Jul 19
Shelf registration
4:03pm
8-K
o0n4ecsmeaqfyr3
25 Jun 19
Material Modifications to Rights of Security Holders
4:15pm
8-K
456k8l cpiv
13 Jun 19
Kezar Life Sciences Announces Promising Data from First in Patient Study of KZR-616 at EULAR 2019 Annual Meeting
4:02pm